These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics. Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936 [TBL] [Abstract][Full Text] [Related]
4. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
5. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
6. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results. Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191 [TBL] [Abstract][Full Text] [Related]
7. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884 [TBL] [Abstract][Full Text] [Related]
8. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299 [TBL] [Abstract][Full Text] [Related]
9. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Kalkanis D; Stefanovic A; Paes F; Escalon MP; Serafini A; Lossos IS Leuk Lymphoma; 2009 Jun; 50(6):904-11. PubMed ID: 19455459 [TBL] [Abstract][Full Text] [Related]